EBS | tickerfilter.com

Fundamental analysis

58%

Profitability 40%

Dept financing 39%

Liquidity 75%

Performance 76%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

10.24%

1 Month

17.81%

3 Months

-50.18%

6 Months

-43.23%

1 Year

190.48%

2 Year

-37.83%

Key data

Stock price

$5.49

P/E Ratio

0.00

DAY RANGE

$5.30 - $5.70

EPS

-$3.60

52 WEEK RANGE

$1.82 - $15.10

52 WEEK CHANGE

$190.48

MARKET CAP

518.001 M

YIELD

N/A

SHARES OUTSTANDING

52.907 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

04-30-2025

BETA

4.55

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,204,086

AVERAGE 30 VOLUME

$1,258,514

Company detail

CEO: Robert G. Kramer
Region: US
Website: emergentbiosolutions.com
Employees: 2,420
IPO year: 2006

Issue type: Common Stock
Market: NYSE
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Emergent BioSolutions focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. Its products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose.

EBS - Emergent BioSolutions Inc.